Recce eyes Indonesia for novel anti-infective as Indo-Aus ties grow stronger
Recce Pharmaceuticals (ASX:RCE) has been on a tear this year. It's developing anti-infective, R327, with clinical results across Diabetic Foot Infection, Acute Bacterial Skin & Skin Structure Infection, and, Urosepsis/UTIs which point to a potential commercial value proposition. It also has a recent key relationship in Indonesia.
Corporate Spotlight
Not Yet Available
Are you a Company Director ?
Put your Investment Case to Hotcopper's 700K monthly unique visitors.
Latest Threads
Tag | Subject | ||||||
---|---|---|---|---|---|---|---|
SIR | Value of S2 | 12/08/16 | 2 | 18K | |||
|
|||||||
SIR | bring on 2012 for sir | 06/11/15 | 2 | 7.9K | |||
|
|||||||
SIR | How good were SIR's initial nickel hits ? | 05/10/15 | 0 | 5.7K | |||
|
|||||||
SIR | Payment | 29/09/15 | 3 | 8.7K | |||
|
|||||||
SIR | News: Matsa Resources now holds $14M in cash and liquid equities | 22/09/15 | 8 | 10K | |||
|
|||||||
SIR | Ann: Removal from Official Quotation (COB 23/09/2015) | 22/09/15 | 0 | 4.1K | |||
|
|||||||
SIR | Last day today | 22/09/15 | 7 | 16K | |||
|
|||||||
SIR | Ann: FY2015 Final Dividend | 22/09/15 | 0 | 2.9K | |||
|
See All Discussions